GE Vernova Inc.
GE Vernova Inc. (GEV) Stock News
The latest GEV headlines and market coverage — 6 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
GE Vernova (GEV) Dips More Than Broader Market: What You Should Know
GE Vernova (GEV) closed down 3.12% but has gained 5.96% over the past month. The energy spinoff from General Electric is expected to report earnings on October 28, 2026, with projected EPS growth of 149.39% and revenue growth of 21.39% year-over-year. However, the stock trades at a premium valuation with a Forward P/E of 35.53 versus the industry average of 17.95, earning a Zacks Rank of #3 (Hold).
- Zacks Investment Research·Neutral
Here is What to Know Beyond Why GE Vernova Inc. (GEV) is a Trending Stock
GE Vernova (GEV), the energy business spun off from General Electric, has outperformed the S&P 500 with a +7.1% return over the past month. The company is expected to report strong earnings growth of +148.8% year-over-year for the current quarter and +72.4% for the fiscal year, with revenue growth of +21.6%. However, the stock carries a Zacks Rank #3 (Hold) rating and is trading at a premium valuation (Grade D) relative to peers, suggesting it may perform in line with the broader market in the near term.
- Zacks Investment Research·
GEV Stock Rises 37.5% YTD: Time to Lock in Gains or Ride the Wave?
GE Vernova (GEV) has surged 37.5% year-to-date, driven by strong demand across power generation and grid modernization tied to electrification, data centers, and AI expansion. The company's backlog reached $176 billion, bolstered by new grid projects in the UK and a South Korea HVDC joint venture. However, GEV trades at a premium valuation (34.22X forward P/E) and faces headwinds from tariffs ($100-200M impact in 2026) and supply chain disruptions. Analysts recommend new investors wait for a better entry point while current holders maintain positions.
- The Motley Fool·
I'm Calling It: GE Vernova (GEV) Is a Buy Before This Catalyst Drops
GE Vernova, spun off from General Electric two years ago, has surged nearly 750% since its market debut. The company operates in Power, Electrification, and Wind segments and is positioned to benefit from the 'AI grid supercycle' driven by hyperscalers and AI infrastructure providers. With a $163 billion backlog and projected revenue growth of 16% CAGR through 2028, analysts view the stock as fairly valued at 36x earnings despite its strong growth prospects.
- Benzinga·
Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders
Vertex Pharmaceuticals reported positive Phase 3 clinical data for CASGEVY in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. All evaluated patients achieved primary endpoints with sustained clinical benefits and a consistent safety profile. The company is pursuing FDA approval to expand the therapy's use to younger children.
- Benzinga·
Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) reported new clinical data showing that CASGEVY (exagamglogene autotemcel) delivered efficacy and safety outcomes in children ages 5 to 11 with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) The data were consistent with results previously observed in adolescent and adult patients. Phase 3 Studies Show High Rates Of Clinical Response An interim analysis from the Phase 3 CLIMB-151 study in children with severe SCD showed all 11 treated patients remained free from vaso-occlusive crises (VOCs). data-variant="card" data-news-mode="manual" > Read Also: Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps Among the eight patients with sufficient follow-up, 100% achieved the primary endpoint of remaining VOC-free for at least 12 ... Full story available on Benzinga.com